The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sanofi SA

NYSE: SNY
Last

(U.S.) $41.20

Today's change-0.06 -0.15%
Updated May 31 4:02 PM EDT. Delayed by at least 15 minutes.
 

Sanofi SA

NYSE: SNY
Last

(U.S.) $41.20

Today's change-0.06 -0.15%
Updated May 31 4:02 PM EDT. Delayed by at least 15 minutes.

Sanofi SA crosses below 50-day moving average

Sanofi SA closed lower Tuesday, dropping (U.S.)$0.06 or 0.15% to (U.S.)$41.20 and crossing below its 50-day moving average. Over the last five days, shares have gained 2.46%, but are down 3.40% for the last year to date. Shares have underperformed the S&P 500 by 16.12% during the last year.

Key company metrics

  • Open(U.S.) $41.26
  • Previous close(U.S.) $41.26
  • High(U.S.) $41.27
  • Low(U.S.) $40.88
  • Bid / Ask(U.S.) $40.86 / (U.S.) $41.50
  • YTD % change-3.40%
  • Volume1,367,082
  • Average volume (10-day)1,338,428
  • Average volume (1-month)1,589,294
  • Average volume (3-month)1,970,704
  • 52-week range(U.S.) $37.63 to (U.S.) $54.98
  • Beta0.98
  • Trailing P/E21.95×
  • P/E 1 year forward9.98×
  • Forward PEG1.41×
  • Indicated annual dividend(U.S.) $1.63
  • Dividend yield3.96%
  • Trailing EPS(U.S.) $1.88
Updated May 31 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+12.82%

Based on its net profit margin of 12.82%, Sanofi SA is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.15%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7,92834,8619,68018,351
Total other revenue--------
Total revenue7,92834,8619,68018,351
Gross profit5,48123,9426,68212,627
Total cost of revenue2,44710,9192,9985,724
Total operating expense6,77429,2877,72514,957
Selling / general / administrative2,2129,3822,4615,086
Research & development1,2355,0821,3552,489
Depreciation / amortization4442,1375981,229
Interest expense (income), net operating--------
Unusual expense (income)5001,612267413
Other operating expenses, total-641554616
Operating income1,1545,5741,9553,394
Interest income (expense), net non-operating---246---132
Gain (loss) on sale of assets--------
Other--------
Income before tax1,0375,2431,8503,189
Income after tax9204,5341,5782,450
Income tax, total117709272739
Net income1,0874,2871,6282,325
Total adjustments to net income--------
Net income before extra. items9874,4111,6282,325
Minority interest-26-101-23-59
Equity in affiliates93-2273-66
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9874,4111,6282,325
Inc. avail. to common incl. extra. items1,0874,2871,6282,325
Diluted net income1,0874,2921,6282,327
Dilution adjustment--5--2
Diluted weighted average shares1,2881,3211,3131,322
Diluted EPS excluding extraordinary itemsvalue per share0.773.341.241.76
Dividends per sharevalue per share0.002.930.000.00
Diluted normalized EPSvalue per share1.114.401.412.00
R